The inactivated coronavirus vaccine developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences has entered phase 2 of clinical trials, according to the Chinese Journal of Science and Technology.
In phase 2 of the studies, the immunogenicity and safety of the vaccine in humans will be further assessed. The trials will be carried out in Yunnan province in the south of the country.
The ongoing Phase 1 study had around 200 participants since May. In phase two, the vaccine dose is determined and the immune response it elicits in healthy people continues to be assessed.
So far, according to the Ministry of Science and Technology, five vaccine candidates for COVID-19 have been approved for clinical trials in China, which accounts for 40 percent of all clinical trial vaccines worldwide.